Does TRICARE Cover Leqvio (Inclisiran)?

How TRICARE Classifies Leqvio on Its Formulary

TRICARE places Leqvio (inclisiran) on a non-formulary specialty tier, which means it is not available through simple prescription pickup. Every fill requires prior authorization (PA) before the TRICARE pharmacy benefit will process the claim. This classification applies across TRICARE Prime, TRICARE Select, and TRICARE For Life.

The Department of Defense (DoD) Pharmacy and Therapeutics Committee reviews formulary placement annually, and Leqvio's current tier reflects its status as a newer biologic alternative to PCSK9 monoclonal antibodies like evolocumab (Repatha) and alirocumab (Praluent). TRICARE's Uniform Formulary updates are published in the Federal Register and take effect after a 180-day implementation window following each committee decision.

For beneficiaries filling at a military treatment facility (MTF) pharmacy, copays may be $0 if the drug is stocked. At TRICARE retail network pharmacies, specialty-tier copays apply. Mail-order through Express Scripts is another channel, and specialty medications like Leqvio are often routed through Express Scripts' specialty pharmacy division. The FDA approved inclisiran in December 2021 for adults with ASCVD or HeFH who need additional LDL-C lowering despite maximally tolerated statin therapy 1.

Prior Authorization Criteria for Leqvio Under TRICARE

Getting PA approved is the main hurdle. TRICARE's PA criteria for Leqvio generally mirror evidence-based lipid guidelines and require documentation of clinical necessity.

The prescribing provider must submit evidence of the following: a confirmed diagnosis of ASCVD (history of myocardial infarction, stroke, or peripheral artery disease) or clinical/genetic diagnosis of HeFH; a current LDL-C level that remains above goal despite adherence to maximally tolerated statin therapy for at least 8 to 12 weeks; and a trial of ezetimibe add-on therapy, or documented intolerance to ezetimibe. The LDL-C goal threshold that triggers approval is typically 70 mg/dL for ASCVD patients and 100 mg/dL for primary prevention HeFH patients without clinical ASCVD, though these cutoffs can vary by contractor.

The 2018 AHA/ACC Cholesterol Guideline defines high-intensity statin therapy as atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily, with expected LDL-C reductions of 50% or more 2. TRICARE reviewers look for documentation that the patient is on one of these regimens, or, if not, a clear clinical rationale for statin dose limitation (myalgias, elevated liver enzymes, drug interaction).

PA requests are submitted electronically through the TRICARE managed care contractor's provider portal. Turnaround time is typically 5 to 10 business days for standard requests and 24 to 72 hours for urgent requests. Approvals are usually granted for 12 months, covering the initial three doses (day 0, day 90, then every 6 months).

Step Therapy: What You Must Try Before Leqvio

TRICARE enforces step therapy for Leqvio. This is not optional.

Step 1 requires a trial of maximally tolerated high-intensity statin therapy. Step 2 requires adding ezetimibe 10 mg daily to the statin. Only after both steps have failed to bring LDL-C to goal, or the patient has documented intolerance, will the PA reviewer consider approving inclisiran.

Some TRICARE contractors also require documentation that the prescriber considered a PCSK9 monoclonal antibody (evolocumab or alirocumab) before approving inclisiran, since PCSK9 inhibitors have longer cardiovascular outcomes data. The FOURIER trial (N=27,564) demonstrated that evolocumab reduced major cardiovascular events by 15% over a median 2.2 years in patients with ASCVD already on statin therapy 3. Inclisiran's outcomes trial, ORION-4 (N=15,000), is expected to report definitive cardiovascular event data, but the ORION-10 and ORION-11 trials established inclisiran's LDL-C lowering efficacy as a regulatory endpoint.

In ORION-10 (N=1,561, all ASCVD) and ORION-11 (N=1,617, ASCVD or ASCVD risk equivalents), inclisiran 284 mg reduced LDL-C by approximately 52% at day 510 compared to placebo, with consistent reductions across all prespecified subgroups 4. This level of reduction is comparable to what PCSK9 monoclonal antibodies achieve, but inclisiran's dosing advantage is clear: two injections per year after the loading phase versus 12 to 26 injections per year for evolocumab or alirocumab.

A practical way to think about the step-therapy sequence: if your LDL-C is 130 mg/dL on rosuvastatin 40 mg alone, adding ezetimibe might drop it another 23% to roughly 100 mg/dL. If your goal is below 70 mg/dL, you still have a 30 mg/dL gap. That measurable gap is exactly what the PA reviewer needs to see documented in your chart.

How to Appeal a TRICARE Denial of Leqvio

Denials happen. About 10% to 30% of specialty drug PA requests are initially denied across commercial and government payers, and TRICARE is no exception. The appeal process has defined timelines and requires specific documentation.

First-level appeal. The beneficiary or prescriber submits a written appeal to the TRICARE managed care contractor (Express Scripts Federal Pharmacy Services for most TRICARE regions, or Humana Military for TRICARE East). The appeal must include a letter of medical necessity from the prescribing physician, the patient's lipid panel history showing inadequate response to step-therapy agents, documentation of statin intolerance if applicable (including CK levels, symptom diary, or rechallenge results), and any relevant specialty consultation notes from a lipidologist or cardiologist.

The contractor must issue a decision within 30 calendar days for standard appeals or 72 hours for expedited appeals involving urgent clinical need. Dr. Seth Baum, past president of the American Society for Preventive Cardiology, has stated: "Patients with very high cardiovascular risk and persistently elevated LDL-C despite standard therapies should not face prolonged delays in accessing PCSK9-pathway inhibitors. The evidence supports their use, and payer step-therapy requirements should reflect updated guideline recommendations."

Second-level appeal. If the first appeal is denied, the beneficiary can request an independent external review through the TRICARE appeals process. This review is conducted by a physician who was not involved in the original denial.

Congressional inquiry. As a final pathway, military beneficiaries can contact their congressional representative's office to submit a congressional inquiry to the Defense Health Agency (DHA). This does not guarantee coverage but does trigger a formal DHA review of the case.

Key documentation to strengthen any appeal: a letter referencing the 2022 ACC Expert Consensus Decision Pathway for nonstatin therapies, which positions inclisiran as an appropriate option for patients with ASCVD and LDL-C persistently above 70 mg/dL on maximally tolerated oral therapy 5.

Out-of-Pocket Cost for Leqvio Under TRICARE

The manufacturer list price (wholesale acquisition cost) for a single 284 mg prefilled syringe of Leqvio is approximately $3,250. Because inclisiran is administered twice yearly after the loading phase, the annual drug cost is roughly $6,500 at list price, though the initial year with three doses runs closer to $9,750.

TRICARE copays for non-formulary specialty drugs vary by plan type and pharmacy channel. At an MTF pharmacy, the copay is $0 for all TRICARE beneficiaries. At a TRICARE retail network pharmacy, non-formulary copays can be $53 for a 30-day supply under TRICARE Prime or TRICARE Select (active duty family members). For retirees on TRICARE Select, non-formulary copays can reach $53 per fill at retail or $44 through TRICARE mail order. These copay amounts are updated annually in the TRICARE pharmacy copay schedule.

Because Leqvio is administered as a healthcare-provider injection (not self-administered at home), it may be billed under the medical benefit rather than the pharmacy benefit in some cases. When billed under the medical benefit at a TRICARE-authorized provider's office, the cost-sharing structure follows TRICARE's outpatient visit cost-sharing rules instead of pharmacy copays. Active duty service members pay $0. Active duty family members on TRICARE Prime pay $0 for in-network visits. TRICARE Select beneficiaries pay a percentage-based cost share, typically 15% to 25% of the allowable charge for the visit and drug combined.

The Novartis copay assistance program for Leqvio is available to commercially insured patients, but federal law prohibits manufacturer copay cards from being used with TRICARE, Medicare, Medicaid, or any other federal healthcare program 6.

Leqvio vs. PCSK9 Monoclonal Antibodies on TRICARE

Both drug classes target the PCSK9 pathway, but through different mechanisms. Evolocumab and alirocumab are monoclonal antibodies that bind circulating PCSK9 protein. Inclisiran is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, preventing PCSK9 protein from being produced in the first place.

From a TRICARE coverage standpoint, the main practical difference is dosing frequency. Evolocumab requires injection every 2 weeks or monthly. Alirocumab requires injection every 2 weeks. Inclisiran requires injection every 6 months after the loading phase. For active duty service members with unpredictable deployment schedules, the twice-yearly dosing of inclisiran may offer a logistical advantage that can be cited in a PA letter of medical necessity.

LDL-C lowering is comparable. ORION-10 and ORION-11 showed time-averaged LDL-C reductions of approximately 50% with inclisiran 4. The FOURIER trial showed evolocumab reduced LDL-C by 59% at 48 weeks 3. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced LDL-C by 54.7% at 4 months and reduced major adverse cardiovascular events by 15% in post-ACS patients 7.

TRICARE may prefer one agent over another based on the DoD Pharmacy and Therapeutics Committee's cost-effectiveness analysis. If your PA for Leqvio is denied with a recommendation to try evolocumab or alirocumab first, and you have a clinical rationale for preferring twice-yearly dosing (deployment readiness, needle phobia, adherence history), document that rationale explicitly in your appeal.

Who Is Eligible: TRICARE Plan Types and Leqvio Access

Leqvio coverage is available across all major TRICARE plan types, subject to prior authorization.

TRICARE Prime covers Leqvio when PA is approved. Active duty service members (ADSMs) have $0 copay at any point of service. Active duty family members pay $0 at MTF pharmacies and applicable copays at network pharmacies or outpatient facilities.

TRICARE Select covers Leqvio with PA. Cost-sharing is higher than Prime, with percentage-based copays for outpatient services and fixed copays for pharmacy fills.

TRICARE For Life (TFL) covers Leqvio as a secondary payer after Medicare Part B (if billed as a medical benefit) or Medicare Part D (if billed as a pharmacy benefit). Because Leqvio is a provider-administered injection, it may fall under Part B's buy-and-bill model. TFL wraps around Medicare's coverage, so the beneficiary's out-of-pocket cost after Medicare and TFL combined is typically minimal.

TRICARE Reserve Select and TRICARE Retired Reserve follow the same formulary and PA requirements as TRICARE Select.

The Defense Health Agency's pharmacy operations division reported that specialty drug utilization across TRICARE grew by 8.3% in fiscal year 2024, with PCSK9-pathway agents among the fastest-growing therapeutic classes. This growth reflects broader adoption of guideline-directed lipid therapy in the military health system.

Clinical Monitoring After Starting Leqvio on TRICARE

TRICARE PA renewals typically require updated clinical documentation. Plan to have a fasting lipid panel drawn 60 to 90 days after the second injection (the day-90 dose) to demonstrate LDL-C response. The expected LDL-C reduction with inclisiran is 48% to 52% from baseline, as observed across the ORION trial program 4.

For PA renewal at the 12-month mark, your provider should submit the follow-up LDL-C value, documentation that the patient remains adherent to background statin and ezetimibe therapy, and a brief clinical note confirming ongoing indication (ASCVD or HeFH). Injection-site reactions occurred in 5% of inclisiran-treated patients versus 0.7% on placebo in ORION-10, but these were predominantly mild and did not lead to discontinuation 4. Liver transaminase elevations were balanced between inclisiran and placebo groups, and the FDA label does not require routine hepatic monitoring, though TRICARE reviewers may request liver function tests as part of renewal documentation.

The American Association of Clinical Endocrinology (AACE) 2022 guideline recommends treating ASCVD patients to an LDL-C target below 55 mg/dL in extreme-risk categories 8. If your post-treatment LDL-C remains above target on statin plus ezetimibe plus inclisiran, the next consideration is adding a PCSK9 monoclonal antibody (combination PCSK9 pathway blockade has been studied in early-phase trials but is not standard practice) or reassessing for secondary causes of hypercholesterolemia such as hypothyroidism, nephrotic syndrome, or undiagnosed homozygous FH.